My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 267

    1.

    Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.

    Pedersen-Bjergaard J, Ersbøll J, Sørensen HM, Keiding N, Larsen SO, Philip P, Larsen MS, Schultz H, Nissen NI.

    Ann Intern Med. 1985 Aug;103(2):195-200.PMID: 4014901 [PubMed - indexed for MEDLINE]Related articles

    2.

    Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.

    Pedersen-Bjergaard J, Larsen SO.

    N Engl J Med. 1982 Oct 14;307(16):965-71.PMID: 7110299 [PubMed - indexed for MEDLINE]Related articles

    3.

    Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

    Pedersen-Bjergaard J, Specht L, Larsen SO, Ersbøll J, Struck J, Hansen MM, Hansen HH, Nissen NI.

    Lancet. 1987 Jul 11;2(8550):83-8.PMID: 2885581 [PubMed - indexed for MEDLINE]Related articles

    4.

    Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.

    Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G, Gadner H.

    J Clin Oncol. 1997 Jun;15(6):2247-53.PMID: 9196137 [PubMed - indexed for MEDLINE]Related articles

    5.

    The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.

    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.

    Haematologica. 1998 Sep;83(9):812-23.PMID: 9825578 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.

    Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ.

    Blood. 1996 May 1;87(9):3625-32.PMID: 8611686 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.

    Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA.

    BMJ. 1992 May 2;304(6835):1137-43.PMID: 1392790 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.

    Pedersen-Bjergaard J, Osterlind K, Hansen M, Philip P, Pedersen AG, Hansen HH.

    Blood. 1985 Dec;66(6):1393-7.PMID: 2998512 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.

    van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R.

    J Clin Oncol. 1994 May;12(5):1063-73.PMID: 8164031 [PubMed - indexed for MEDLINE]Related articles

    10.

    Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas.

    Lavey RS, Eby NL, Prosnitz LR.

    Cancer. 1990 Jul 1;66(1):80-8.PMID: 2354413 [PubMed - indexed for MEDLINE]Related articles

    11.

    Melphalan may be a more potent leukemogen than cyclophosphamide.

    Greene MH, Harris EL, Gershenson DM, Malkasian GD Jr, Melton LJ 3rd, Dembo AJ, Bennett JM, Moloney WC, Boice JD Jr.

    Ann Intern Med. 1986 Sep;105(3):360-7.PMID: 3740675 [PubMed - indexed for MEDLINE]Related articles

    12.

    Acute nonlymphocytic leukemia after treatment for Hodgkin's disease.

    Aisenberg AC.

    Am J Med. 1983 Sep;75(3):449-54.PMID: 6688502 [PubMed - indexed for MEDLINE]Related articles

    13.

    Acute leukemia after alkylating-agent therapy of ovarian cancer.

    Reimer RR, Hoover R, Fraumeni JF Jr, Young RC.

    N Engl J Med. 1977 Jul 28;297(4):177-81.PMID: 406560 [PubMed - indexed for MEDLINE]Related articles

    14.

    Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients.

    Pedersen-Bjergaard J, Philip P, Pedersen NT, Hou-Jensen K, Svejgaard A, Jensen G, Nissen NI.

    Cancer. 1984 Aug 1;54(3):452-62.PMID: 6733676 [PubMed - indexed for MEDLINE]Related articles

    15.

    Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).

    Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J.

    Leuk Lymphoma. 2001 Feb;40(5-6):499-509.PMID: 11426523 [PubMed - indexed for MEDLINE]Related articles

    16.

    Second acute leukemia and other malignancies following treatment for Hodgkin's disease.

    Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G.

    J Clin Oncol. 1986 Jun;4(6):830-7.PMID: 3711960 [PubMed - indexed for MEDLINE]Related articles

    17.

    Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).

    Boice JD Jr, Greene MH, Killen JY Jr, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni JF Jr.

    N Engl J Med. 1983 Nov 3;309(18):1079-84.PMID: 6353233 [PubMed - indexed for MEDLINE]Related articles

    18.

    Hodgkin's disease: study of treatment intensities and incidences of second malignancies.

    Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F Jr, et al.

    Ann Oncol. 1993 Feb;4(2):125-31.PMID: 8448080 [PubMed - indexed for MEDLINE]Related articles

    19.

    Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.

    Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H.

    Ann Hematol. 1994 Mar;68(3):105-10.PMID: 8167175 [PubMed - indexed for MEDLINE]Related articles

    20.

    Acute leukemia following prolonged cytotoxic agent therapy.

    Casciato DA, Scott JL.

    Medicine (Baltimore). 1979 Jan;58(1):32-47. Review.PMID: 105227 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity